Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 16/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13844700 | 0.93 | PTGER2 (0.49) | PTGER2PTGER4HRH3 | |
| SCHEMBL13844706 | 0.88 | PTGER2 (0.50) | PTGER2PTGER4HRH3SMN1; SMN2CYP2C19 | |
| SCHEMBL13844753 | 0.86 | PTGER4 (0.52) | PTGER2PTGER4HRH3 | |
| SCHEMBL13844764 | 0.83 | NPC1 (0.46) | PTGER2PTGER4SMN1; SMN2CYP2C19 | |
| SCHEMBL13844763 | 0.82 | ALDH1A1 (0.43) | PTGER2PTGER4HRH3SMN1; SMN2 | |
| SCHEMBL13844707 | 0.82 | PTGER2 (0.45) | PTGER2PTGER4CYP2C19 | |
| SCHEMBL13844792 | 0.81 | PTGER2 (0.51) | PTGER2PTGER4HRH3 | |
| SCHEMBL14113063 | 0.80 | PTGER2 (0.79) | PTGER2PTGER4HRH3SMN1; SMN2 | |
| SCHEMBL13844777 | 0.80 | PTGER2 (0.43) | PTGER2PTGER4 | |
| SCHEMBL13844762 | 0.79 | PTGER4 (0.46) | PTGER2PTGER4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER2 39/4885PTGER4 33/4885HRH3 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.